Dr Lal PathLabs

May 03, 2017

The National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex, Bandra (E)
Mumbai - 400051

The Bombay Stock Exchange Limited
15th Floor, Phiroze Jeejeeboy Towers
Dalal Street,
Mumbai – 400001

**Subject: Intimation of Conference Call for Investors/ Analyst for Q4 & FY 17**

**Ref: Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirement) Regulations 2015**

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirement) Regulations 2015, please find attached the invite of the Conference Call for Investors/ Analysts to be held on Friday, May 12, 2017 at 4.30 PM IST to discuss financial and operating performance for Q4 & FY 17.

You are requested to take note of the above.

Thanking You,

Yours Faithfully,

For **Dr. Lal PathLabs Limited**

Dr. Lal PathLabs Limited

**Rajat Kalra**
**Company Secretary & Legal Head**

Encl: As above

12th Floor, Tower B, SAS Tower, Medicity, Sector-38, Gurgaon-122001, Haryana.

# Q4 & FY17 Earnings Conference Call
# Friday, May 12, 2017 at 4:30 pm IST

**Gurgaon, May 03, 2017:**

**Dr Lal PathLabs Ltd. (DLPL)** will be hosting a conference call to discuss its Q4 & FY17 results. DLPL will be represented by (Hony.) Brig. Dr. Arvind Lal - Chairman and Managing Director, Dr. Om Prakash Manchanda - Whole-time Director and CEO and Mr. Dilip Bidani - CFO.

The conference call will be initiated with a brief discussion by the management on the Q4 & FY17 financial and operating performance, which will be announced on the same day. Following this, there will be an opportunity for participants to get their queries addressed during the call.

Details of the conference call are as follows:

| | |
|---|---|
| **Time** | • **04:30 pm IST on Friday, May 12, 2017** |
| **Conference dial –in – India Access** | • **+91 22 3938 1071** |
| **Local Access Number** | • **3940 3977**<br>Available in - Ahmedabad, Bangalore, Chandigarh, Chennai, Gurgaon (NCR), Hyderabad, Kochi/Cochin, Kolkata, Lucknow, Pune. Accessible from all carriers. |
| **Conference dial-in – International Toll Number** | • **USA - 13233868721** |
| | • **UK - 442034785524** |
| | • **Singapore - 6531575746** |
| | • **Hong Kong - 85230186877** |
| **Replay** | • **+91 22 3065 2322**<br>• 66436 (passcode)<br>• Valid from May 12, 2017 to May 19, 2017 |

-ENDS-

**About Dr Lal PathLabs Limited (DLPL)**

Dr Lal PathLabs Limited is one of India's leading consumer healthcare brand in diagnostic services.

It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests and services for use in: core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions. The services of DLPL are aimed at individual patients, hospitals and other healthcare providers and corporates. The catalogue of services includes 1,110 test panels, 1,934 pathology tests and 1,561 radiology and cardiology tests.

As on March 31, 2016 DLPL's has 172 clinical labs (including National Reference Lab at Delhi), 1,559 Patient Service Centers (PSCs) and 4,967 Pick-up Points (PUPs). In FY2015 and FY16, DLPL collected and processed approximately 21.7 million samples and 26.3 million samples from approximately 9.9 million and 12 million patients, respectively.

Additional information on Dr Lal PathLabs Limited:
Corporate Identification No: L74899DL1995PLC065388
Website: https://www.lalpathlabs.com/

**For further information please contact:**


Dilip Bidani
Dr Lal PathLabs Limited
Tel: +91 124 301 6500
Fax: +91 124 423 4468
E-mail: dilip.bidani@lalpathlabs.com

Siddharth Rangnekar / Urvashi Butani
CDR,India
Tel: +91 22 66451209 / 1219
Fax: +91 22 66451213
Email: siddharth@cdr-india.com
urvashi@cdr-india.com